Highly sensitive detection of the PIK3CAH1047R mutation in colorectal cancer using a novel PCR-RFLP method
暂无分享,去创建一个
Jin Fang | Lin-Lin Zhou | Wan-Ming Li | Ting-Ting Hu | Yi-Ming Feng | Yun-Yi Wang | Tingting Hu | Linlin Zhou | Jin Fang | Wanming Li | Yiming Feng | Yun-Yi Wang
[1] L. Mazzucchelli,et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] P. Gascón,et al. Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab , 2011, Tumor Biology.
[3] Sabine Tejpar,et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.
[4] Francesca Molinari,et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.
[5] M. Loda,et al. Polymerase chain reaction-based methods for the detection of mutations in oncogenes and tumor suppressor genes. , 1994, Human pathology.
[6] Hidetoshi Inoko,et al. Single nucleotide polymorphism detection by polymerase chain reaction-restriction fragment length polymorphism , 2007, Nature Protocols.
[7] D. Jäger,et al. [Systemic therapy for colorectal cancer]. , 2005, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.
[8] R. Lothe,et al. Epigenetic and genetic features of 24 colon cancer cell lines , 2013, Oncogenesis.
[9] Charles Swanton,et al. Genetic prognostic and predictive markers in colorectal cancer , 2011, Nature Reviews Cancer.
[10] R. Henrique,et al. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer , 2013, BMC Cancer.
[11] Jinyao Ning,et al. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials , 2014, Tumor Biology.
[12] Lewis C. Cantley,et al. AKT/PKB Signaling: Navigating Downstream , 2007, Cell.
[13] L. Borsu,et al. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants , 2015, Molecular Cancer Research.
[14] S. Pauker,et al. Summary of recommendations: The Evaluation of Genomic , 2022 .
[15] G. Fucharoen,et al. Known and new hemoglobin A2 variants in Thailand and implication for β-thalassemia screening. , 2015, Clinica chimica acta; international journal of clinical chemistry.
[16] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[17] Jianying Zhou,et al. Clinical Features and Gene Mutations of Lung Cancer Patients 30 Years of Age or Younger , 2015, PloS one.
[18] Masahiro Ito,et al. A Rapid and Simple Detection Method for the BRAFT1796A Mutation in Fine-Needle Aspirated Thyroid Carcinoma Cells , 2004 .
[19] B. Park,et al. Mutation of the PIK3CA oncogene in human cancers , 2006, British Journal of Cancer.
[20] E. Zwarthoff,et al. Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes , 2010, PloS one.
[21] Renzo Boldorini,et al. Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer , 2011, Clinical Cancer Research.
[22] D. Lambrechts,et al. PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer , 2009, Clinical Cancer Research.
[23] Y. Nakagawa,et al. A simple method of detecting K-ras point mutations in stool samples for colorectal cancer screening using one-step polymerase chain reaction/restriction fragment length polymorphism analysis. , 2002, Clinica chimica acta; international journal of clinical chemistry.
[24] Victor Moreno,et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction , 2012, Gut.
[25] W. Scheithauer,et al. Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Zhangrun Xu,et al. Detection of Low-Abundance KRAS Mutations in Colorectal Cancer Using Microfluidic Capillary Electrophoresis-Based Restriction Fragment Length Polymorphism Method with Optimized Assay Conditions , 2013, PloS one.
[27] M. A. Marcello,et al. mRNA BRAF expression helps to identify papillary thyroid carcinomas in thyroid nodules independently of the presence of BRAFV600E mutation. , 2012, Pathology, research and practice.
[28] Mef Nilbert,et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis , 2014, Acta oncologica.
[29] Y. Samuels,et al. Oncogenic PI3K and its role in cancer , 2006, Current opinion in oncology.
[30] Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes , 2013, BMC Cancer.
[31] M. Schlaak,et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations , 2014, BMC Cancer.
[32] J. Neumann,et al. Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis , 2013, Virchows Archiv.
[33] Zuyao Yang,et al. Promising biomarkers for predicting the outcomes of patients with KRAS wild‐type metastatic colorectal cancer treated with anti‐epidermal growth factor receptor monoclonal antibodies: A systematic review with meta‐analysis , 2013, International journal of cancer.
[34] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[35] Carlo Rago,et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.
[36] J. L. Tang,et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] G. Luo,et al. Clinical Significance of a Point Mutation in DNA Polymerase Beta (POLB) Gene in Gastric Cancer , 2015, International journal of biological sciences.
[38] G. Fucharoen,et al. High resolution melting analytical platform for rapid prenatal and postnatal diagnosis of β-thalassemia common among Southeast Asian population. , 2015, Clinica chimica acta; international journal of clinical chemistry.
[39] Ji Luo,et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.
[40] S. Erdamar,et al. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS , 2014, Tumor Biology.
[41] P. Ross,et al. The role of the PI3K pathway in colorectal cancer. , 2015, Critical reviews in oncology/hematology.
[42] Jim F Huggett,et al. Considerations for digital PCR as an accurate molecular diagnostic tool. , 2015, Clinical chemistry.
[43] S. Gallinger,et al. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. , 2006, Journal of the American College of Surgeons.
[44] A. Wu,et al. KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing. , 2011, Clinica chimica acta; international journal of clinical chemistry.